Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921404 | 0.79 | GSK3A (0.53) | KDM4EMAPTALDH1A1 | |
| SCHEMBL4923038 | 0.78 | KMT2A (0.51) | TSHRMAPTALDH1A1 | |
| SCHEMBL9831615 | 0.71 | TACR1 (0.57) | KDM4ETSHRTP53NPC1MAPT | |
| SCHEMBL31190634 | 0.71 | ELANE (0.48) | KDM4EMAPTALDH1A1 | |
| SCHEMBL2657547 | 0.69 | CA1 (0.35) | MAPTALDH1A1 | |
| SCHEMBL9830022 | 0.69 | KDM4E (0.68) | KDM4ETSHRTP53NPC1MAPT | |
| SCHEMBL805159 | 0.69 | HSD17B10 (0.65) | HSD17B10IDO1ADRA1ATAAR1MAPT | |
| SCHEMBL7264952 | 0.68 | MEN1 (0.48) | HSD17B10KDM4ETSHRALDH1A1 | |
| SCHEMBL487942 | 0.67 | HSD17B10 (0.62) | HSD17B10IDO1ADRA1ATAAR1HTR2A | |
| SCHEMBL21538245 | 0.67 | KDM4E (0.67) | KDM4ETSHRTP53NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | HSD17B10 1559/4885KDM4E 2357/4885TSHR 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.